OnCo
drugsTreatmentPhase 2

Peluntamig

aka Peluntamig (PT217)

Peluntamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and neuroendocrine tumours, aimed at CD47 and DLL3.